The FDA will form a new advisory committee of outside specialists to advise the agency on how to inform the public about the risks and benefits of medicines and medical devices. The Risk Communication Advisory Committee will:
The committee "will bring together a broad range of experts and views to help improve the FDA's communication of the science-based information about product risks and benefits that the public needs to make informed decisions."
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs